(HealthDay News) — Ixekizumab (Taltz) appears beneficial in reducing the pain and disability of psoriatic arthritis, according to research published online May 24 in The Lancet.
Mark Genovese, MD, a professor of immunology and rheumatology at the Stanford University Medical Center in California, and colleagues focused on more than 363 adult patients with psoriatic arthritis across 10 countries who were no longer seeing an effect from standard biologic drugs or had never experienced a benefit. Patients were randomly assigned to receive injections of either ixekizumab or an inactive placebo. Over six months, about one-third received ixekizumab injections every two weeks, another third received the placebo every two weeks, while the remaining third received alternate injections of ixekizumab and the placebo.
The researchers found that more than half (53%) of those treated with ixekizumab experienced at least a 20% reduction in the number of tender and swollen joints, compared to 19.5% of those receiving the placebo. There was little difference in heightened vulnerability to infectious disease between patients taking ixekizumab and those on a placebo (infections reported in 39% of patients with ixekizumab every four weeks; 38% with ixekizumab every two weeks, and 30% with placebo).
“Both the two-week and four-week ixekizumab dosing regimens improved the signs and symptoms of patients with active psoriatic arthritis and who had previously inadequate response to tumor necrosis factor inhibitors, with a safety profile consistent with previous studies investigating ixekizumab,” the authors conclude.
The study was funded by Eli Lilly & Co, the manufacturer of ixekizumab.
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)